Combination of Somatostatin Analog, Dexamethasone, and Standard Androgen Ablation Therapy in Stage D3 Prostate Cancer Patients with Bone Metastases
Open Access
- 1 July 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (13) , 4398-4405
- https://doi.org/10.1158/1078-0432.ccr-04-0077
Abstract
Purpose: Androgen ablation-refractory prostate cancer patients (stage D3) develop painful bone metastases and limited responsiveness to conventional therapies, hence the lack of universally accepted “gold standard” treatment for this poor prognosis clinical setting. We tested the safety and efficacy in stage D3 patients of the combination hormonal therapy, which combines administration of somatostatin analog and dexamethasone with standard androgen ablation monotherapy (luteinizing-hormone releasing-hormone analog or orchiectomy).Keywords
This publication has 30 references indexed in Scilit:
- Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancerExpert Opinion on Investigational Drugs, 2001
- Tartrate-Resistant Acid Phosphatase 5b: A Novel Serum Marker of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG‐63 human osteosarcoma cellsInternational Journal of Cancer, 1995
- Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC‐3 prostate cancer cellsThe Prostate, 1995
- Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancerJournal of Bone and Mineral Research, 1994
- Mitogenic effects of insulin and insulin‐like growth factors on PA‐III rat prostate adenocarcinoma cells: Characterization of the receptors involvedThe Prostate, 1991
- Effects of human prostatic mitogens on rat bone cells and fibroblastsJournal of Endocrinology, 1987
- Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766)The Prostate, 1987
- Selective osteoblast mitogens can be extracted from prostatic tissueThe Prostate, 1986
- Long‐term follow‐up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: Classification of variables associated with disease outcomeThe Prostate, 1985